MACROGENICS, INC. Increase (Decrease) in Other Current Liabilities
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Other Current Liabilities of -$916.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-03-09
- MACROGENICS, INC. increase (decrease) in other current liabilities for the quarter ending 2022-12-31 was $0.00.
- MACROGENICS, INC. increase (decrease) in other current liabilities for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in other current liabilities for the quarter ending 2021-09-30 was $258.00K, a 67.83% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in other current liabilities for the quarter ending 2021-06-30 was -$258.00K, a 127.80% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in other current liabilities for fiscal 2025 was -$916.00K, a 153.57% decline from fiscal 2024.
- MACROGENICS, INC. increase (decrease) in other current liabilities for fiscal 2024 was $1.71M.
- MACROGENICS, INC. increase (decrease) in other current liabilities for fiscal 2023 was $0.00.
- MACROGENICS, INC. increase (decrease) in other current liabilities for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month | Increase (Decrease) in Other Current Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$916.00K 10-K · filed 2026-03-09 | ||||
| 2024-12-31 | $1.71M 10-K · filed 2026-03-09 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-03-09 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | ||||
| 2021-09-30 | $258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $258.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$258.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | |||
| 2021-03-31 | $258.00K 10-Q · filed 2022-05-03 | ||||
| 2020-09-30 | $802.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.73M derived: sum of 2 quarters · filed 2021-11-02 | $2.25M 10-Q · filed 2021-11-02 | $2.25M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | $928.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $1.44M 10-Q · filed 2021-07-29 | $1.44M derived: sum of 3 quarters · filed 2021-07-29 | $1.44M derived: sum of 4 quarters · filed 2021-07-29 | |
| 2020-03-31 | $515.00K 10-Q · filed 2021-04-29 | $515.00K derived: sum of 2 quarters · filed 2021-04-29 | $515.00K derived: sum of 3 quarters · filed 2021-04-29 | $515.00K derived: sum of 4 quarters · filed 2021-04-29 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 derived: sum of 3 quarters · filed 2020-11-04 | $0.00 10-K · filed 2020-02-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-05 | ||||
| 2018-12-31 | -$298.00K 10-K · filed 2020-02-25 | ||||
| 2017-12-31 | -$1.59M 10-K · filed 2020-02-25 | $0.00 10-K · filed 2018-02-27 | |||
| 2016-12-31 | -$3.55M 10-K · filed 2019-02-26 | -$727.00K 10-K · filed 2017-02-28 | |||
| 2015-12-31 | -$878.00K 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $1.24M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |